Results 31 to 40 of about 108,288 (261)
Background Cervical thymoma is a rare thymic epithelial neoplasm. Evidence supports an increased risk of second primary malignancies in patients with thymoma.
Chutima Kunacheewa +2 more
doaj +1 more source
Background Mediastinal gray zone lymphoma is a newly recognized entity with transitional morphological and immunophenotypic features between the nodular sclerosis subtype of Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma.
Franziska C. Eberle +13 more
doaj +1 more source
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition
Diffuse large B-cell lymphoma is the most common subtype of lymphoma, representing ∼25 % of non-Hodgkin lymphoid malignancies. EZH2 is highly expressed in Diffuse large B-cell lymphoma and ∼22 % of patients contain EZH2 mutations.
Chenyun He +3 more
doaj +1 more source
Diffuse large B-cell lymphoma with uncommon cardiac invasion
Diffuse large B-cell lymphoma is the most common histologic subtype of non-Hodgkin lymphoma. Secondary involvement of the heart is seen late in advanced cases, it is uncommon for diffuse large B-cell lymphoma to present as intracardiac mass.
Yunis Daralammouri +4 more
doaj +1 more source
SnapShot: Diffuse Large B Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma (NHL) in adulthood, comprising 30%–40% of all new diagnoses. This aggressive disease can arise de novo or, less frequently, from the clinical evolution of various indolent B cell malignancies. While durable remissions can be achieved in a substantial proportion of cases by
PASQUALUCCI, Laura, Dalla Favera R.
openaire +3 more sources
The forkhead transcription factor FOXP1 is generally regarded as an oncogene in activated B cell-like diffuse large B-cell lymphoma. Previous studies have suggested that a small isoform of FOXP1 rather than full-length FOXP1, may possess this oncogenic ...
Martine van Keimpema +8 more
doaj +1 more source
Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and is often treated with chemotherapy, autologous stem cell transplant, and chimeric antigen receptor (CAR-T) cell therapy.
Mishi Bhushan, Kirthi R. Kumar
doaj +1 more source
Background Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.Design and Methods We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin’s lymphomas of
Pier Paolo Piccaluga +11 more
doaj +1 more source
Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma
Background FoxM1 has been shown to play a critical role in the pathogenesis of various epithelial malignancies. However, its role in lymphoid malignancies has not been fully clarified.
Shahab Uddin +6 more
doaj +1 more source
Non-Hodgkin’s Lymphoma in Buccal Vestibule -Case Report [PDF]
Lymphomas are malignant neoplasms arising from lymphocytes B cell or T cell that affects mainly lymph nodes, spleen and other non hematopoietic tissues. They are classified as Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell
Indira Reddy +4 more
doaj +1 more source

